Antibody-drug conjugates: recent advances in conjugation and linker chemistries
Kyoji Tsuchikama(), Zhiqiang An
Texas Therapeutics Institute, The Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center at Houston, Houston, TX 77054, USA
The antibody-drug conjugate (ADC), a humanized or human monoclonal antibody conjugated with highly cytotoxic small molecules (payloads) through chemical linkers, is a novel therapeutic format and has great potential to make a paradigm shift in cancer chemotherapy. Thisnewantibody-based molecular platform enables selective delivery of a potent cytotoxic payload to target cancer cells, resulting in improved efficacy, reduced systemic toxicity, and preferable pharmacokinetics (PK)/ pharmacodynamics (PD) and biodistribution compared to traditional chemotherapy. Boosted by the successes of FDA-approved Adcetris® and Kadcyla®, this drug class has been rapidly growing along with about 60 ADCs currently in clinical trials. In this article, we briefly review molecular aspects of each component (the antibody, payload, and linker) of ADCs, and then mainly discuss traditional and new technologies of the conjugation and linker chemistries for successful construction of clinically effective ADCs. Current efforts in the conjugation and linker chemistries will provide greater insights into molecular design and strategies for clinically effective ADCs from medicinal chemistry and pharmacology standpoints. The development of site-specific conjugation methodologies for constructing homogeneousADCs is an especially promising path to improving ADC design, which will open the way for novel cancer therapeutics.
An Z (2010) Monoclonal antibodies—a proven and rapidly expanding therapeutic modality for human diseases. Protein Cell 1:319–330
2
Axup JY, Bajjuri KM, Ritland M, Hutchins BM, Kim CH, Kazane SA, Halder R, Forsyth JS, Santidrian AF, Stafin Ket al. (2012) Synthesis of site-specific antibody-drug conjugates using unnatural amino acids. Proc Natl Acad Sci USA 109:16101–16106
3
Beerli RR, Hell T, Merkel AS, Grawunder U (2015) Sortase enzymemediated generation of site-specifically conjugated antibody drug conjugates with high in vitro and in vivo potency. PLoS ONE 10: e0131177
4
Behrens CR, Ha EH, Chinn LL, Bowers S, Probst G, Fitch-Bruhns M, Monteon J, Valdiosera A, Bermudez A, Liao-Chan Set al. (2015) Antibody-drug conjugates (ADCs) derived from interchain cysteine cross-linking demonstrate improved homogeneity and other pharmacological properties over conventional heterogeneous ADCs. Mol Pharm 12:3986–3998
5
Bouchard H, Viskov C, Garcia-Echeverria C (2014) Antibody–drug conjugates—a new wave of cancer drugs. Bioorg Med Chem Lett 24:5357–5363
6
Bryant P, Pabst M, Badescu G, Bird M, McDowell W, Jamieson E, Swierkosz J, Jurlewicz K, Tommasi R, Henseleit Ket al. (2015) In vitro and in vivo evaluation of cysteine rebridged trastuzumab–MMAE antibody drug conjugates with defined drug-to-antibody ratios. Mol Pharm 12:1872–1879
7
Bryden F, Maruani A, Savoie H, Chudasama V, Smith MEB, Caddick S, Boyle RW (2014) Regioselective and stoichiometrically controlled conjugation of photodynamic sensitizers to a HER2 targeting antibody fragment. Bioconjugate Chem 25:611–617
8
Chari RVJ (2008) Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc Chem Res 41:98–107
9
Chari RVJ, Miller ML, Widdison WC (2014) Antibody-drug conjugates: an emerging concept in cancer therapy. Angew Chem Int Ed Engl 53:3796–3827
10
Chudasama V, Maruani A, Caddick S (2016) Recent advances in the construction of antibody-drug conjugates. Nat Chem 8:114–119
11
Damelin M, Zhong W, Myers J, Sapra P (2015) Evolving strategies for target selection for antibody-drug conjugates. Pharm Res 32:3494–3507
12
Dennler P, Chiotellis A, Fischer E, Brégeon D, Belmant C, Gauthier L, Lhospice F, Romagne F, Schibli R (2014) Transglutaminasebased chemo-enzymatic conjugation approach yields homogeneous antibody-drug conjugates. Bioconjugate Chem 25:569–578
13
DeVita VT, Chu E (2008) A history of cancer chemotherapy. Cancer Res 68:8643–8653
14
Diamantis N, Banerji U (2016) Antibody-drug conjugates-an emerging class of cancer treatment. Br J Cancer 114:362–367
15
Drake PM, Rabuka D (2015) An emerging playbook for antibodydrug conjugates: lessons from the laboratory and clinic suggest a strategy for improving efficacy and safety. Curr Opin Chem Biol 28:174–180
16
Dubowchik GM, Firestone RA, Padilla L, Willner D, Hofstead SJ, Mosure K, Knipe JO, Lasch SJ, Trail PA (2002) Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity. Bioconjugate Chem 13:855–869
17
Ehrlich P (1913) Address in pathology, ON CHEMIOTHERAPY: delivered before the seventeenth International Congress of Medicine. Br Med J 2:353–359
18
Finbloom DS, Abeles D, Rifai A, Plotz PH (1980) The specificity of uptake of model immune complexes and other protein aggregates by the murine reticuloendothelial system. J Immunol 125:1060–1065
19
Ford CH, Newman CE, Johnson JR, Woodhouse CS, Reeder TA, Rowland GF, Simmonds RG (1983) Localisation and toxicity study of a vindesine-anti-CEA conjugate in patients with advanced cancer. Br J Cancer 47:35–42
20
Gondi CS, Rao JS (2013) Cathepsin B as a cancer target. Expert Opin Ther Targets 17:281–291
21
Hartley JA (2011) The development of pyrrolobenzodiazepines as antitumour agents. Expert Opin Investig Drugs 20:733–744
22
Jain N, Smith SW, Ghone S, Tomczuk B (2015) Current ADC linker chemistry. Pharm Res 32:3526–3540
23
Jeger S, Zimmermann K, Blanc A, Grünberg J, Honer M, Hunziker P, Struthers H, Schibli R (2010) Site-specific and stoichiometric modification of antibodies by bacterial transglutaminase. Angew Chem Int Ed Engl 49:9995–9997
24
Junutula JR, Raab H, Clark S, Bhakta S, Leipold DD, Weir S, Chen Y, Simpson M, Tsai SP, Dennis MSet al. (2008) Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol 26:925–932
25
Kern JC, Cancilla M, Dooney D, Kwasnjuk K, Zhang R, Beaumont M, Figueroa I, Hsieh S, Liang L, Tomazela Det al. (2016) Discovery of pyrophosphate diesters as tunable, soluble, and bioorthogonal linkers for site-specific antibody-drug conjugates. J Am Chem Soc 138:1430–1445
26
King HD, Dubowchik GM, Mastalerz H, Willner D, Hofstead SJ, Firestone RA, Lasch SJ, Trail PA (2002) Monoclonal antibody conjugates of doxorubicin prepared with branched peptide linkers: inhibition of aggregation by methoxytriethyleneglycol chains. J Med Chem 45:4336–4343
27
Kung Sutherland MS, Walter RB, Jeffrey SC, Burke PJ, Yu C, Kostner H, Stone I, Ryan MC, Sussman D, Lyon RPet al. (2013) SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drugresistant AML. Blood 122:1455–1463
28
Laguzza BC, Nichols CL, Briggs SL, Cullinan GJ, Johnson DA, Starling JJ, Baker AL, Bumol TF, Corvalan JR (1989) New antitumor monoclonal antibody-vinca conjugates LY203725 and related compounds: design, preparation, and representative in vivo activity. J Med Chem 32:548–555
29
Lazar AC, Wang L, Blättler WA, Amphlett G, Lambert JM, Zhang W (2005) Analysis of the composition of immunoconjugates using size-exclusion chromatography coupled to mass spectrometry. Rapid Commun Mass Spectrom 19:1806–1814
30
Lencer WI, Blumberg RS (2005) A passionate kiss, then run: exocytosis and recycling of IgG by FcRn. Trends Cell Biol 15:5–9
31
Linenberger ML, Hong T, Flowers D, Sievers EL, Gooley TA, Bennett JM, Berger MS, Leopold LH, Appelbaum FR, Bernstein ID (2001) Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin. Blood 98:988–994
32
LoRusso PM, Weiss D, Guardino E, Girish S, Sliwkowski MX (2011) Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. Clin Cancer Res 17:6437–6447
33
Lyon RP, Bovee TD, Doronina SO, Burke PJ, Hunter JH, Neff-LaFord HD, Jonas M, Anderson ME, Setter JR, Senter PD (2015) Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index. Nat Biotechnol 33:733–735
34
Madej MP, Coia G, Williams CC, Caine JM, Pearce LA, Attwood R, Bartone NA, Dolezal O, Nisbet RM, Nuttall SDet al. (2012) Engineering of an anti-epidermal growth factor receptor antibody to single chain format and labeling by Sortase A-mediated protein ligation. Biotechnol Bioeng 109:1461–1470
35
Maruani A, Smith MEB, Miranda E, Chester KA, Chudasama V, Caddick S (2015) A plug-and-play approach to antibody-based therapeutics via a chemoselective dual click strategy. Nat Commun 6:6645
36
Mathe G, Loc TB, Bernard J (1958) Effect on mouse leukemia 1210 of a combination by diazo-reaction of amethopterin and gammaglobulins from hamsters inoculated with such leukemia by heterografts. C R Hebd Seances Acad Sci 246:1626–1628
37
McCombs JR, Owen SC (2015) Antibody drug conjugates: design and selection of linker, payload and conjugation chemistry. AAPS J 17:339–351
38
Mills BJ, Lang CA (1996) Differential distribution of free and bound glutathione and cyst(e)ine in human blood. Biochem Pharmacol 52:401–406
39
Mullard A (2013) Maturing antibody-drug conjugate pipeline hits 30. Nat Rev Drug Discov 12:329–332
40
Perez HL, Cardarelli PM, Deshpande S, Gangwar S (2014) Antibody–drug conjugates: current status and future directions. Drug Discov Today 19:869–881
41
Polson AG, Ho WY, Ramakrishnan V (2011) Investigational antibody-drug conjugates for hematological malignancies. Expert Opin Investig Drugs 20:75–85
42
Popp MWL, Antos JM, Ploegh HL (2009) Site-specific protein labeling via sortase-mediated transpeptidation. Curr Protoc Protein Sci. doi:10.1002/0471140864.ps1503s56
43
Postow MA, Callahan MK, Wolchok JD (2015) Immune checkpoint blockade in cancer therapy. J Clin Oncol 33:1974–1982
44
Rudnick SI, Lou J, Shaller CC, Tang Y, Klein-Szanto AJP, Weiner LM, Marks JD, Adams GP (2011) Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors. Cancer Res 71:2250–2259
45
Saito G, Swanson JA, Lee K-D (2003) Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities. Adv Drug Deliv Rev 55:199–215
46
Sedlacek HH, Seemann G, Hoffmann D, Czech J (1992) Antibodies as carriers of cytotoxicity. Contrib Oncol 43:1–145
47
Sievers EL, Larson RA, Stadtmauer EA, Estey E, Löwenberg B, Dombret H, Karanes C, Theobald M, Bennett JM, Sherman MLet al. (2001) Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 19:3244–3254
48
Strop P, Liu S-H, Dorywalska M, Delaria K, Dushin RG, Tran T-T, Ho W-H, Farias S, Casas MG, Abdiche Yet al. (2013) Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates. Chem Biol 20:161–167
49
Swee LK, Guimaraes CP, Sehrawat S, Spooner E, Barrasa MI, Ploegh HL (2013) Sortase-mediated modification of αDEC205 affords optimization of antigen presentation and immunization against a set of viral epitopes. Proc Natl Acad Sci USA 110:1428–1433
50
Teicher BA, Chari RVJ (2011) Antibody conjugate therapeutics: challenges and potential. Clin Cancer Res 17:6389–6397
51
ten Cate B, Bremer E, de Bruyn M, Bijma T, Samplonius D, Schwemmlein M, Huls G, Fey G, Helfrich W (2009) A novel AMLselective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability. Leukemia 23:1389–1397
52
Tian F, Lu Y, Manibusan A, Sellers A, Tran H, Sun Y, Phuong T, Barnett R, Hehli B, Song Fet al. (2014) A general approach to site-specific antibody drug conjugates. Proc Natl Acad Sci. USA 111:1766–1771
53
Tolcher AW, Sugarman S, Gelmon KA, Cohen R, Saleh M, Isaacs C, Young L, Healey D, Onetto N, Slichenmyer W (1999) Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. J Clin Oncol 17:478–484
54
van Geel R, Wijdeven MA, Heesbeen R, Verkade JMM, Wasiel AA, van Berkel SS, van Delft FL (2015) Chemoenzymatic conjugation of toxic payloads to the globally conserved n-glycan of native mAbs provides homogeneous and highly efficacious antibodydrug conjugates. Bioconjugate Chem 26:2233–2242
55
VanBrunt MP, Shanebeck K, Caldwell Z, Johnson J, Thompson P, Martin T, Dong H, Li G, Xu H, D’Hooge Fet al. (2015) Genetically encoded azide containing amino acid in mammalian cells enables site-specific antibody-drug conjugates using click cycloaddition chemistry. Bioconjugate Chem 26:2249–2260
56
Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram M, Oh D-Y, Diéras V, Guardino Eet al. (2012) Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367:1783–1791
Widdison W, Wilhelm S, Veale K, Costoplus J, Jones G, Audette C, Leece B, Bartle L, Kovtun Y, Chari R (2015) Metabolites of antibody-maytansinoid conjugates: characteristics and in vitro potencies. Mol Pharm 12:1762–1773
59
Witte MD, Cragnolini JJ, Dougan SK, Yoder NC, Popp MW, Ploegh HL (2012) Preparation of unnatural N-to-N and C-to-C protein fusions. Proc Natl Acad Sci USA 109:11993–11998
60
Wu G, Fang Y-Z, Yang S, Lupton JR, Turner ND (2004) Glutathione metabolism and its implications for health. J Nutr 134:489–492
61
Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, Forero-Torres A (2010) Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 363:1812–1821
62
Zhao RY, Wilhelm SD, Audette C, Jones G, Leece BA, Lazar AC, Goldmacher VS, Singh R, Kovtun Y, Widdison WCet al. (2011) Synthesis and evaluation of hydrophilic linkers for antibodymaytansinoid conjugates. J Med Chem 54:3606–3623
63
Zhou Q, Stefano JE, Manning C, Kyazike J, Chen B, Gianolio DA, Park A, Busch M, Bird J, Zheng Xet al. (2014) Site-specific antibody-drug conjugation through glycoengineering. Bioconjugate Chem 25:510–520
64
Zimmerman ES, Heibeck TH, Gill A, Li X, Murray CJ, Madlansacay MR, Tran C, Uter NT, Yin G, Rivers PJet al. (2014) Production of site-specific antibody-drug conjugates using optimized non-natural amino acids in a cell-free expression system. Bioconjugate Chem 25:351–361
